Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Mason, L. Kalinowski, R. Jacob, Adam Jacoby, T. Malinski (2005)
Nebivolol Reduces Nitroxidative Stress and Restores Nitric Oxide Bioavailability in Endothelium of Black AmericansCirculation, 112
M. Bristow, P. Nelson, W. Minobe, C. Johnson (2005)
P-121: Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardiumAmerican Journal of Hypertension, 18
J. Boni, C. Leister, G. Bender, V. Fitzpatrick, N. Twine, J. Stover, A. Dorner, F. Immermann, M. Burczynski (2005)
Population Pharmacokinetics of CCI‐779: Correlations to Safety and Pharmacogenomic Responses in Patients with Advanced Renal CancerClinical Pharmacology & Therapeutics, 77
N. Tzemos, P. Lim, T. MacDonald (2001)
Nebivolol Reverses Endothelial Dysfunction in Essential Hypertension: A Randomized, Double-Blind, Crossover StudyCirculation: Journal of the American Heart Association, 104
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension, 42 6
T. Pronko, V. Zinchuk (2009)
Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertensionClinical Physiology and Functional Imaging, 29
M.R. Bristow, P. Nelson, W. Winobe (2005)
Characterization of β1-adrenergic receptor selectivity of nebivolol and various other β-blockers in human myocardium [abstract no. P-121]Am J Hypertens, 18
T.L. Morton, S. Liu, J.L. Phillips (2005)
Pharmacokinetics of nebivolol and ramipril are not affected by co-administration [abstract no. PII-101]Clin Pharmacol Ther, 77
E. Saunders, W. Smith, K. Desalvo, W. Sullivan (2007)
The Efficacy and Tolerability of Nebivolol in Hypertensive African American PatientsThe Journal of Clinical Hypertension, 9
M.D. Moen, A.J. Wagstaff (2006)
Nebivolol: a review of its use in the management of hypertension and chronic heart failureDrugs, 66
A. Himmelmann, T. Hedner, E. Snoeck, B. Lundgren, J. Hedner (1996)
Haemodynamic effects and pharmacokinetics of oral d-and l-nebivolol in hypertensive patientsEuropean Journal of Clinical Pharmacology, 51
E. Arosio, S. Marchi, M. Prior, M. Zannoni, A. Lechi (2002)
Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stressJournal of Hypertension, 20
W. McNeely, K.L. Goa (1999)
Nebivolol in the management of essential hypertension: a reviewDrugs, 57
S. Evangelista, U. Garbin, A. Pasini, C. Stranieri, V. Boccioletti, L. Cominacini (2007)
Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells.Pharmacological research, 55 4
A. Bonartsev, A. Postnikov, V. Myshkina, M. Artemieva, N. Medvedeva, G. Bonartseva, A. Iordansky (2005)
P-119: A new system of nitric oxide donor prolonged delivery on basis of controlled-release polymer, polyhydroxybutyrateAmerican Journal of Hypertension, 18
T. Morton, H. Tu, S. Liu, S. Chervenick, R. Rackley, M. Huang (2005)
Lack of pharmacokinetic interaction between nebivolol and spironolactoneClinical Pharmacology & Therapeutics, 77
V. Papademetriou (2009)
Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.The American journal of cardiology, 103 2
S.E. Brett, P. Forte, P.J. Chowienczyk (2002)
Comparison of the effects of nebivolol and bisoprolol on systemic vascular resistance in patients with essential hypertension: β-blockade and haemodynamics in hypertensionClin Drug Investig, 22
T. Morton, S. Liu, J. Phillips, C. Donnelly, R. Rackley (2005)
Pharmacokinetics of nebivolol and ramipril are not affected by co‐administrationClinical Pharmacology & Therapeutics, 77
(2007)
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus: hypertension managementEndocr Pract, 13
Azra Mahmud, J. Feely (2008)
Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.American journal of hypertension, 21 6
T.E. Lawrence, S. Liu, J.W. Fisher (2005)
No interaction between nebivolol and digoxin in healthy volunteers [abstract no. PII-98]Clin Pharmacol Ther, 77
T. Morton, S. Liu, J. Phillips, C. Donnelly, R. Rackley (2005)
No pharmacokinetic interaction between nebivolol and furosemide in healthy subjectsClinical Pharmacology & Therapeutics, 77
L. Bi, K. Huynh, Stan Louie, N. Hoem, Jane Kriengkauykiat, Mark Gill, P. Beringer (2005)
Bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosisClinical Pharmacology & Therapeutics, 77
R. Mason (2006)
Nitric Oxide Mechanisms in the Pathogenesis of Global RiskThe Journal of Clinical Hypertension, 8
W. Roberts, H. Black, G. Bakris, R. Mason, T. Giles, D. Sulkes (2007)
The editor's roundtable: revisiting the role of beta blockers in hypertension.The American journal of cardiology, 100 2
T.L. Morton, H.C. Tu, S. Liu (2005)
Lack of pharmacokinetic interaction between nebivolol and spironolactone [abstract no. PI-148]Clin Pharmacol Ther, 77
T. Lawrence, C. Chien, H. Tu, J. Phillips, C. Donnelly, M. Huang (2005)
No effect of concomitant administration of nebivolol and losartan in healthy volunteers genotyped for CYP2D6 statusClinical Pharmacology & Therapeutics, 77
S. Brett, Pablo Forte, Philip Chowienczyk, N. Benjamin, James Ritter (2002)
Comparison of the Effects of Nebivolol and Bisoprolol on Systemic Vascular Resistance in Patients with Essential HypertensionClinical Drug Investigation, 22
A. Zanchetti (2004)
Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide‐mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patientsBlood Pressure, 13
Sandeep Gupta, H. Wright (2008)
Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.Cardiovascular therapeutics, 26 3
B. Knorr, L. Maganti, R. Ramakrishnan, P. Larson, C. Tozzi, T. Reiss (2005)
Population pharmacokinetic profile of montelukast in children aged 3 to 6 months with bronchiolitisClinical Pharmacology & Therapeutics, 77
F. Kamali, A. Howes, S. Thomas, G. Ford, E. Snoeck (2003)
A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine.British journal of clinical pharmacology, 43 2
T. Quang, T. Quang, B. Rozec, Leslie Audigane, Leslie Audigane, Leslie Audigane, C. Gauthier, C. Gauthier, C. Gauthier (2009)
Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aortaBritish Journal of Pharmacology, 156
L. Ignarro (2004)
Experimental evidences of nitric oxide‐dependent vasodilatory activity of nebivolol, a third‐generation β‐blockerBlood Pressure, 13
T. Lawrence, S. Liu, J. Fisher, T. Vukic‐Bugarski, C. Donnelly, M. Huang, R. Rackley (2005)
No interaction between nebivolol and digoxin in healthy volunteersClinical Pharmacology & Therapeutics, 77
A. Pasini, U. Garbin, C. Stranieri, V. Boccioletti, C. Mozzini, Stefania Manfro, A. Pasini, Mattia Cominacini, L. Cominacini (2008)
Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.American journal of hypertension, 21 11
T.E. Lawrence, C. Chien, H.C. Tu (2005)
No effect of concomitant administration of nebivolol and losartan in healthy volunteers genotyped for CYP2D6 status [abstract no. PII-121]Clin Pharmacol Ther, 77
A.A. Shaw, S. Liu, L.F. Zachwieja (2005)
Effect of chronic administration of fluoxetine on the pharmacokinetics of nebivolol [abstract no. PI-116]Clin Pharmacol Ther, 77
U. Hillebrand, D. Lang, R. Telgmann, C. Hagedorn, S. Reuter, K. Kliche, C. Stock, H. Oberleithner, H. Pavenstädt, E. Büssemaker, M. Hausberg (2009)
Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging studyJournal of Hypertension, 27
G. Sunkara, C. Thang‐Dittman, C. Yeh, M. Ligueros‐Saylan, P. Prasad, N. Masuda, N. Koseki, Y. Fukui (2005)
Assessment of ethnic differences in the pharmacokinetics of valsartanClinical Pharmacology & Therapeutics, 77
A. Water, W. Janssens, J. Neuten, R. Xhonneux, J. Crée, H. Verhaegen, R. Reneman, P. Janssen (1988)
Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.Journal of cardiovascular pharmacology, 11 5
T.L. Morton, S. Liu, J.L. Phillips (2005)
No pharmacokinetic interaction between nebivolol and furosemide in healthy subjects [abstract no. PII-107]Clin Pharmacol Ther, 77
T.E. Lawrence, S. Liu, T.M. Bland (2005)
Single-dose pharmacokinetics and anticoagulant activity of warfarin is unaffected by nebivolol in healthy volunteers [abstract no. PI-121]Clin Pharmacol Ther, 77
L. Ignarro (2008)
Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.Cardiovascular therapeutics, 26 2
R. Weiss, Michael Weber, A. Carr, W. Sullivan (2007)
A Randomized, Double‐Blind, Placebo‐Controlled Parallel‐Group Study to Assess the Efficacy and Safety of Nebivolol, a Novel β‐Blocker, in Patients With Mild to Moderate HypertensionThe Journal of Clinical Hypertension, 9
▲ Nebivolol is a β-adrenergic receptor antagonist with a dual mechanism of action. It shows high selectivity for β1-adrenergic receptors and appears to have nitric oxide-mediated vasodilatory activity.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.